3107 - Prospective Serum Lipidomic Profiling Identifies Predictive Biomarkers for nCRT Response and Tumor Regression in Advanced Esophageal Cancer

05:00pm - 06:00pm PT

Hall F

Screen: 17

POSTER

Presenter(s)

Zheng Xiumei, - Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan

Z. Xiumei¹, T. Chengxi², H. Wenwu², H. Bai³, W. Xiao³, L. Peng³, G. Liu³, K. Wang³, Q. Fang³, Q. Yunxiang⁴, L. Liang³, X. Leng², Y. Han³, and J. Lv³; ¹Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China, ²Department of Radiation oncology, Sichuan Clinical ResearchCenter for Cancer, Sichuan Cancer Hospital & Institute, SichuanCancerCenter,School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China, ³Sichuan Clinical Research Center for Cancer,Sichuan Hospital Cancer & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China, ⁴Department of Radiation oncology, Radiation Oncology KeyLaboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, SichuanCancerCenter, University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Purpose/Objective(s):

The purpose of this study was to prospectively detect dynamic changes of serum lipid of patients with esophageal cancer (EC) before and after neoadjuvant chemoradiotherapy (nCRT), and to identify lipid metabolites associated with therapeutic response and tumor regression. We aim to find potential biomarkers and a typical lipid signature for predicting treatment efficacy and guiding personalized therapeutic strategies.

Materials/Methods:

This prospective observational cohort study enrolled 17 patients diagnosed with locally advanced esophageal cancer who received neoadjuvant chemoradiotherapy (nCRT) from January 2024 to December 2024. The chemotherapy regimen consisted of albumin-bound paclitaxel and carboplatin. The radiation dose was 41.4 Gy. Based on tumor regression scores, patients were categorized into the experimental group (grade 0, n=9) and the control group (grades 1–2, n=8). Paired serum samples were collected before and after treatment for comparative analysis.

Results:

A total of 359 lipid metabolites were detected by liquid chromatography–mass spectrometry (LC-MS). Among these, 14 lipids exhibited significant differences between the two groups, including 10 phosphatidylcholines (PC 12:0_24:3, PC 16:0_22:4, PC 13:0_19:1, PC 21:0_14:1, PC 38:3, PC 16:0_16:1, PC 33:1, PC 30:0, PC 18:2_22:3, PC 40:4), 2 phosphatidylinositols (PI 38:3, PI 36:4), 1 lysophosphatidylcholine (LPC 20:1-SN1), and 1 phosphatidylethanolamine (PE O-18:1_18:1). All of these differentially expressed lipids were upregulated in the experimental group.

Conclusion:

This study prospectively characterizes lipid remodeling in esophageal cancer, identifying phosphatidylcholines (PCs) and phosphatidylinositols (PIs) as key metabolites associated with tumor regression. The upregulated lipid panel demonstrates potential as a predictive biomarker for therapeutic response. These findings underscore the potential of lipid metabolites to enhance risk stratification and guide adaptive chemoradiotherapy strategies.